AbouEzzeddine OF, Davies DR, Scott CG, et al. - A substantial number of heart failure (HF) with preserved ejection fraction (HFpEF) patients with ventricular wall thickening, especially older men, were suffering from transthyretin amyloid cardiomyopathy (ATTR-CM) and therefore, considering systematic screening for ATTR-CM in older patients (particularly men) with heart failure, preserved ejection fraction, and ventricular wall thickening is recommended.

• This population-based cohort study included 1235 HFpEF patients, including a community cohort (median age, 80 years; 630 [51%] male) and a community screening cohort (n = 286; median age, 78 years; 150 [52%] male).

• Clinically recognized ATTR-CM was present in only 16 of 1235 such patients (1.3%; all men).

• The prevalence was estimated to be 2.5% in men and 0% in women.

• ATTR-CM was found to be present in 6.3% of 286 patients (10.0% of men and 2.2% of women) when a systematic screening strategy incorporating technetium Tc 99m pyrophosphate scintigraphy and reflex testing was applied.